Share Issue/Capital Change • Oct 16, 2019
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.
Capital Measures 16.10.2019
Vienna - Marinomed Biotech AG: aws Mittelstandsfonds Beteiligungs GmbH & Co. KG and Invest Unternehmensbeteiligungs AG sold 95,000 Marinomed shares by way of an accelerated bookbuilding for EUR 95 per share to institutional investors; upsize option in an amount of additional 20,000 shares exercised
Vienna, 16. October 2019.
Marinomed Biotech AG (the "Company") announces that the Company was informed by the two shareholders aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws Mittelstandsfonds") and Invest Unternehmensbeteiligungs AG ("Invest AG") on 16 October 2019 that aws Mittelstandsfonds and Invest AG have sold in total 115,000 Marinomed shares from their holdings through an accelerated bookbuilding transaction to institutional investors (the "Transaction").
The following information, put in quotation marks, is taken from the notfication of the Company by aws Mittelstandsfonds and Invest AG:
"NOT FOR DISTRIBUTION OR PUBLICATION, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, CANADA, JAPAN OR AUSTRALIA.
aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws Mittelstandsfonds") and Invest Unternehmensbeteiligungs AG ("Invest AG") hereby announce that today, 16 October 2019, each of aws Mittelstandsfonds and Invest AG have sold 47,500 shares in Marinomed Biotech AG (ISIN ATMARINOMED6, "Marinomed shares"), thus in aggregate 95,000 Marinomed shares, from their holdings to institutional investors by means of an accelerated bookbuilding transaction (the "ABB"). This amounts to 6.5% of Marionomed Biotech AG's share capital. The upsize alternative of up to 45,000 additional Marinomed shares was exercised in an amount of 20,000 additional Marinomed shares.
The Marinomed shares were sold for EUR 95.00 each. The total sale proceeds of the ABB for aws Mittelstandsfonds and Invest AG therefore amounts to EUR 10.93 million. Settlement of Marinomed shares placed in the ABB is scheduled for 18 October 2019.
Erste Group Bank AG acted as the sole bookrunner.
Following completion of the ABB, aws Mittelstandsfonds and Invest AG each still hold approximately 3.2% of the share capital of Marinomed Biotech AG. For these shares the lock-up commitment of aws Mittelstandsfonds and Invest AG, which was entered into as part of the IPO, continues to apply.
Disclaimer:
This announcement constitutes neither an offer to buy securities nor a solicitation of an offer to buy securities in the United States of America, Germany, Austria or other countries. The securities are not sold or offered to be sold in the United States of America under the rules of the US Securities Act of 1933, as amended. The shares have already been placed.
A public offer of the securities was neither made in Austria nor in any other jurisdiction. Any offer of shares under the ABB was made solely on the basis of an exemption from the obligation to publish a prospectus in accordance with Article 1 (4) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and was exclusively intended for qualified investors within the meaning of Article 2 (e) of the Prospectus Regulation."
Further inquiry note:
Dr. Eva Prieschl-Grassauer Chief Scientific Officer, Marinomed Veterinärplatz 1, 1210 Vienna, Austria T +43 (0)1 250 77 4460 E-Mail: [email protected] http://www.marinomed.com
Roland Mayrl Managing Partner, Metrum Communications Bauernmarkt 10/19, 1010 Vienna, Austria T +43 (0) 1 504 69 87 331 E-Mail: [email protected] http://www.metrum.at
end of announcement euro adhoc --------------------------------------------------------------------------------
| issuer: | Marinomed Biotech AG |
|---|---|
| Veterinärplatz 1 | |
| A-1210 Wien | |
| phone: | 0043250774460 |
| FAX: | 0043250774493 |
| mail: | [email protected] |
| WWW: | www.marinomed.com |
| ISIN: | ATMARINOMED6, AT0000A1WD52 |
| indexes: | |
| stockmarkets: Wien | |
| language: | English |
Aussendung übermittelt durch euro adhoc The European Investor Relations Service
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.